SUPPLY ARRANGEMENT - LABORATORY ANALYSIS OF RAW MATERIALS AND FINISHED PRODUCTS (Stream 1,2 and,3)

This contract involves a supply arrangement for laboratory analysis services to support the National Research Council of Canada's new Clinical Trial Material Facility. The facility is designed for the production and quality control of vaccines and biologics, including protein, viral vector, and virus-like particle products. The contract requires adherence to Canadian Good Manufacturing Practices, FDA current Good Manufacturing Practices, and European Eudralex regulations to ensure the quality and compliance of raw materials, solutions, products, and cell banks. Services are organized into three distinct streams: Stream 1 focuses on raw material analysis, Stream 2 covers various solutions and biological product analysis, and Stream 3 deals with cell bank characterization, aligned with the specifications outlined in the Statement of Work. The solicitation, under the title "SUPPLY ARRANGEMENT - LABORATORY ANALYSIS OF RAW MATERIALS AND FINISHED PRODUCTS (Stream 1, 2, and 3)," was posted by the Government of Canada's National Research Council with a response deadline of March 24, 2026. The contract will be performed in Canada, and the contracting authority is Cindy Romain, who can be contacted via email or phone. This arrangement is crucial to supporting the facility's compliance and ensuring the consistent quality and safety of clinical trial materials used in vaccine and biologic production.